Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis.Antimicrobial Agents and Chemotherapy.  63. 2019
2019 Performance of the T2bacteria panel for diagnosing bloodstream infectionsAnnals of Internal Medicine.  170:845-852. 2019
2019 Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE TrialClinical Infectious Diseases.  68:1981-1989. 2019
2019 Impact of infectious disease consultation on clinical management and mortality in patients with candidemiaClinical Infectious Diseases.  68:1585-1587. 2019
2018 Improvement of gram-negative susceptibility to fluoroquinolones after implementation of a pre-authorization policy for fluoroquinolone use: A decade-long experienceInfection Control and Hospital Epidemiology.  39:1419-1424. 2018
2018 Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort studyTransplant Infectious Disease.  20. 2018
2018 Echinocandin resistance among Candida isolates at an academic medical centre 2005-15: Analysis of trends and outcomesJournal of Antimicrobial Chemotherapy.  73:1677-1680. 2018
2018 Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida PanelClinical Infectious Diseases.  66:1678-1686. 2018
2018 Invasive candidiasisNature Reviews Disease Primers.  4. 2018
2018 Efficacy of T2 magnetic resonance assay in monitoring candidemia after initiation of antifungal therapy: The serial therapeutic and antifungal monitoring protocol (STAMP) trialJournal of Clinical Microbiology.  56. 2018
2018 Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipientsTransplant Infectious Disease.  20. 2018
2018 Management of an Outbreak of Exophiala dermatitidis Bloodstream Infections at an Outpatient Oncology ClinicClinical Infectious Diseases.  66:959-962. 2018
2018 Antibody and B cell subset perturbations in human immunodeficiency virus-uninfected patients with cryptococcosisOpen Forum Infectious Diseases.  5. 2018
2017 Thinking beyond the common Candida species: Need for species-level identification of Candida due to the emergence of multidrug-resistant Candida aurisJournal of Clinical Microbiology.  55:3324-3327. 2017
2017 In Memorium: William Ernest Dismukes 1939-2017.Journal of Infectious Diseases2017
2017 Late-onset cerebral toxoplasmosis after allogeneic hematopoietic stem cell transplantationThe American Journal of Case Reports.  18:246-250. 2017
2017 Infections in hematopoietic cell transplant recipients: Results from the organ transplant infection project, a multicenter, prospective, cohort studyOpen Forum Infectious Diseases.  4. 2017
2017 A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases.Open Forum Infectious Diseases.  4:ofx200. 2017
2017 The case for adopting the "species complex" nomenclature for the etiologic agents of cryptococcosismSphere.  2. 2017
2016 The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)Transplant Infectious Disease.  18:921-931. 2016
2016 Reply to Simon and to Eljaaly and Nix.Clinical Infectious Diseases.  63:287-288. 2016
2016 Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysisLancet Infectious Diseases.  16:828-837. 2016
2016 Cryptococcal osteomyelitis: A report of 5 cases and a review of the recent literatureMycoses.  59:334-342. 2016
2016 Invasive CandidiasisInfectious Disease Clinics of North America.  30:103-124. 2016
2016 Comparison between liposomal formulations of amphotericin BMedical Mycology.  54:223-231. 2016
2016 Acute cryptococcal immune reconstitution inflammatory syndrome in a patient on natalizumabOpen Forum Infectious Diseases.  3. 2016
2016 Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: A retrospective observational cohort study of the Mycoses Study Group (MSG-12)Journal of Antimicrobial Chemotherapy.  71:3536-3539. 2016
2015 Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases.  62:e1-e50. 2015
2015 Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases.  62:409-417. 2015
2015 Update on multistate outbreak of fungal infections associated with contaminated methylprednisolone injections, 2012-2014MMWR : Morbidity & Mortality Weekly Report.  64:1200-1201. 2015
2015 A paradoxical decline: Intracranial lesions in two HIV-positive patients recovering from cryptococcal meningitisBMJ Case Reports.  2015. 2015
2015 Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison with Antigen TestingClinical Infectious Diseases.  61:1293-1303. 2015
2015 Reply to Bauer and GoffClinical Infectious Diseases.  61:487-488. 2015
2015 Combination antifungal therapy for invasive aspergillosis a randomized trialAnnals of Internal Medicine.  162:81-89. 2015
2015 Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases GroupClinical Infectious Diseases.  60:713-720. 2015
2015 Cytomegalovirus appendicitis in solid organ transplant patients, two cases and a reviewJournal of Clinical Virology.  66:48-50. 2015
2015 Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET)Medical Mycology.  53:440-446. 2015
2015 T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trialClinical Infectious Diseases.  60:892-899. 2015
2014 Reversible blindness in cryptococcal meningitis with normal intracranial pressure: Case report and review of the literatureClinical Infectious Diseases.  59:310-313. 2014
2014 MORTALITY AFTER CLINICAL MANAGEMENT OF AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN KENYAEast African Medical Journal.  91:145-151. 2014
2014 Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipientsTransplantation.  97:446-450. 2014
2014 Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: Results from an open-label trialBMC Infectious Diseases.  14. 2014
2014 Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida speciesMycoses.  57:79-89. 2014
2014 An expanded role for therapeutic lumbar punctures in newly diagnosed aids-associated cryptococcal meningitis?Clinical Infectious Diseases.  59:1615-1617. 2014
2014 Antifungal clinical trials and guidelines: What we know and do not knowCold Spring Harbor perspectives in medicine.  4. 2014
2014 Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET)Transplant Infectious Disease.  16:213-224. 2014
2014 Epidemiology of invasive mold infections in lung transplant recipientsAmerican Journal of Transplantation.  14:1328-1333. 2014
2014 MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care settingClinical Infectious Diseases.  58:1219-1226. 2014
2014 Race and invasive fungal infection in solid organ transplant recipientsEthnicity and Disease.  24:382-385. 2014
2014 Target lesions in a neutropenic patientInternal and Emergency Medicine.  9:593-595. 2014
2014 The Evolving Epidemiology of SporotrichosisCurrent Fungal Infection Reports.  8:255-261. 2014
2013 Lessons learned in the multistate fungal infection outbreak in the United StatesCurrent Opinion in Infectious Diseases.  26:545-550. 2013
2013 Cryptococcal infections: Changing epidemiology and implications for therapyDrugs.  73:495-504. 2013
2013 Real-time treatment guidelines: Considerations during the Exserohilum rostratum outbreak in the United StatesAntimicrobial Agents and Chemotherapy.  57:1573-1576. 2013
2013 Predictors of Mortality and Differences in Clinical Features among Patients with Cryptococcosis According to Immune StatusPLoS ONE.  8. 2013
2013 Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosisMedical Mycology.  51:128-135. 2013
2013 Cryptococcal infections in non-HIV-infected patients.Transactions- American Clinical and Climatological Association.  124:61-79. 2013
2013 Fungal infections associated with contaminated methylprednisolone injectionsNew England Journal of Medicine.  368:2495-2500. 2013
2013 Prototheca wickerhamii algaemia presenting as cholestatic hepatitis in a patient with systemic lupus erythematosus: A case report and literature reviewMedical Mycology Case Reports.  2:19-22. 2013
2012 Prevention and treatment of cancer-related infectionsJournal of the National Comprehensive Cancer Network.  10:1412-1445. 2012
2012 Pneumocystis pneumonia in hospitalized patients: A detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected personsTransplant Infectious Disease.  14:510-518. 2012
2012 Reply to Anaissie and Nucci and to Cisneros et alClinical Infectious Diseases.  55:894-895. 2012
2012 Fatal burkholderia gladioli infection misidentified as empedobacter brevis in a lung transplant recipient with cystic fibrosisTransplant Infectious Disease.  14. 2012
2012 Association between Vancomycin-resistant enterococci bacteremia and ceftriaxone usageInfection Control and Hospital Epidemiology.  33:718-724. 2012
2012 Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemiaAntimicrobial Agents and Chemotherapy.  56:3133-3137. 2012
2012 Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilutionJournal of Clinical Microbiology.  50:2040-2046. 2012
2012 Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trialsClinical Infectious Diseases.  54:1110-1122. 2012
2012 Micafungin for candidiasisMycoses.  55:8-12. 2012
2011 Pulmonary cryptococcosisSeminars in Respiratory and Critical Care Medicine.  32:727-734. 2011
2011 Pulmonary fungal infectionsSeminars in Respiratory and Critical Care Medicine.  32:661-662. 2011
2011 Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant diseaseMycoses.  54. 2011
2011 Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patientsInternational Journal of STD and AIDS.  22:665-670. 2011
2011 Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: A multivariate analysis of factors associated with improved outcomeBMC Infectious Diseases.  11. 2011
2011 Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in KenyaMycoses.  54. 2011
2011 In Vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the transplant-associated infection surveillance networkAntimicrobial Agents and Chemotherapy.  55:3944-3946. 2011
2011 Ocular manifestations of candidemiaClinical Infectious Diseases.  53:262-268. 2011
2011 The role of azoles in the treatment of invasive mycoses: Review of the infectious diseases society of America guidelinesCurrent Opinion in Infectious Diseases.  24. 2011
2011 Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006Journal of Clinical Microbiology.  49:2404-2410. 2011
2011 Candidemia in the intensive care unit: Miles to go before we sleepCritical Care Medicine.  39:884-885. 2011
2011 IAccumulated safety data of micafungin in therapy and prophylaxis in fungal diseasesExpert Opinion on Drug Safety.  10:171-183. 2011
2011 Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unitMycoses.  54:46-51. 2011
2011 Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006Emerging Infectious Diseases.  17:1855-1864. 2011
2010 Reply to Hoenigl et alClinical Infectious Diseases.  51:254-255. 2010
2010 Cryptococcal meningitis: Current approaches to management in patients with and without AIDSCurrent Infectious Disease Reports.  12:299-305. 2010
2010 Factors associated with mortality in transplant patients with invasive aspergillosisClinical Infectious Diseases.  50:1559-1567. 2010
2010 Cerebral infarction from acquired immunodeficiency syndrome-related cryptococcal meningitis: An overlooked complication of a common opportunistic infection?Infectious Diseases in Clinical Practice.  18:198-200. 2010
2010 Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (Transnet)Clinical Infectious Diseases.  50:1101-1111. 2010
2010 Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant- associated infection surveillance network (TRANSNET) databaseClinical Infectious Diseases.  50:1091-1100. 2010
2010 Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patientsHIV Medicine.  11:276-281. 2010
2010 Blastomycosis of the central nervous system: A multicenter review of diagnosis and treatment in the modern eraClinical Infectious Diseases.  50:797-804. 2010
2010 Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of AmericaClinical Infectious Diseases.  50:291-322. 2010
2010 Cryptococcosis in the developing world: An elephant in the parlorClinical Infectious Diseases.  50:345-346. 2010
2010 International collaboration between US and Thailand on a clinical trial of treatment for HIV-associated cryptococcal meningitisControlled Clinical Trials.  31:34-43. 2010
2010 The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya.East African Medical Journal.  87:481-487. 2010
2009 Candida in solid organ transplant recipientsAmerican Journal of Transplantation.  9. 2009
2009 Effect of high-dose fluconazole on QT interval in patients with human immunodeficiency virus (HIV)-associated cryptococcal meningitisInternational Journal of Antimicrobial Agents.  34:494-496. 2009
2009 Molecular identification of Aspergillus species collected for the transplant-associated infection surveillance networkJournal of Clinical Microbiology.  47:3138-3141. 2009
2009 Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection surveillance networkJournal of Clinical Microbiology.  47:3271-3275. 2009
2009 Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter studyClinical Infectious Diseases.  49:931-934. 2009
2009 Reply to kontoyiannisClinical Infectious Diseases.  49:639-640. 2009
2009 Cryptococcal disease presenting as necrotizing cellulitis in transplant recipients: Case reportTransplant Infectious Disease.  11:353-358. 2009
2009 A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitisClinical Infectious Diseases.  48:1775-1783. 2009
2009 Blastomycosis: New Insights into Diagnosis, Prevention, and TreatmentClinics in Chest Medicine.  30:227-239. 2009
2009 Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases.  48:503-535. 2009
2009 Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS.  23:525-530. 2009
2009 Outcomes of antifungal prophylaxis in high-risk liver transplant recipientsTransplant Infectious Disease.  11:40-48. 2009
2009 Risk factors for acquisition of endemic blastomycosisCanadian Journal of Infectious Diseases.  20:117-121. 2009
2008 Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapyDiagnostic Microbiology and Infectious Disease.  62:151-156. 2008
2008 Pulmonary cryptococcosis in patients without HIV infection: Factors associated with disseminated diseaseEuropean Journal of Clinical Microbiology and Infectious Diseases.  27:937-943. 2008
2008 Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus CriteriaClinical Infectious Diseases.  47:674-683. 2008
2008 Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (Clinical Infectious Diseases (2007) 45, (883-893))Clinical Infectious Diseases.  47:302. 2008
2008 Clinical practice guidelines for the management of blastomycosis: 2008 Update by the infectious diseases society of AmericaClinical Infectious Diseases.  46:1801-1812. 2008
2008 Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases.  46:1813-1821. 2008
2008 Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitisInternational Journal of STD and AIDS.  19:268-271. 2008
2008 Reply to Eiland et al.Clinical Infectious Diseases.  46:641. 2008
2008 Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosisInfection Control and Hospital Epidemiology.  29:25-30. 2008
2007 Clinical practice guidelines for the management of sporotrichosis: 2007 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases.  45:1255-1265. 2007
2007 Combination antifungal therapy for the treatment of invasive yeast and mold infectionsCurrent Infectious Disease Reports.  9:448-456. 2007
2007 Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasisClinical Infectious Diseases.  45:883-893. 2007
2007 Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patientsMedical Mycology.  45:513-518. 2007
2007 Nonsporulating clinical isolate identified as Petromyces alliaceus (Anamorph Aspergillus alliaceus) by morphological and sequence-based methodsJournal of Clinical Microbiology.  45:2701-2703. 2007
2007 Anidulafungin versus fluconazole for invasive candidiasisNew England Journal of Medicine.  356:2472-2482. 2007
2007 Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care settingEuropean Journal of Clinical Microbiology and Infectious Diseases.  26:271-276. 2007
2007 Design and methodology of the Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR-ICU) trial [1]Infection Control and Hospital Epidemiology.  28:245-246. 2007
2006 Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubtClinical Infectious Diseases.  43:1031-1039. 2006
2006 Invasive CandidiasisInfectious Disease Clinics of North America.  20:485-506. 2006
2006 Invasive fungal pathogens: Current epidemiological trendsClinical Infectious Diseases.  43. 2006
2006 Authors' reply [8]Lancet.  367:729. 2006
2006 Invasive fungal infections in low-risk liver transplant recipients: A multi-center prospective observational studyAmerican Journal of Transplantation.  6:386-391. 2006
2006 Invasive candidiasis in the intensive care unitCritical Care Medicine.  34:857-863. 2006
2005 Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trialLancet.  366:1435-1442. 2005
2005 Activity of posaconazole in the treatment of central nervous system fungal infectionsJournal of Antimicrobial Chemotherapy.  56:745-755. 2005
2005 Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humansClinical Infectious Diseases.  41:654-659. 2005
2005 Antifungal combination therapy: Clinical potentialDrugs.  65:1461-1480. 2005
2005 Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance programMedical Mycology.  43. 2005
2005 Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitisAntimicrobial Agents and Chemotherapy.  49:952-958. 2005
2005 Managing cryptococcal meningitis is about handling the pressureClinical Infectious Diseases.  40:480-482. 2005
2004 Fungemia caused by Zygoascus hellenicus in an allogeneic stem cell transplant recipientJournal of Clinical Microbiology.  42:3363-3365. 2004
2004 Recombinant interferon-γ1b as adjunctive therapy for AIDS-related acute cryptococcal meningitisJournal of Infectious Diseases.  189:2185-2191. 2004
2004 BlastomycosisSeminars in Respiratory and Critical Care Medicine.  25:113-121. 2004
2004 Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day-1) in the treatment of cutaneous or lymphocutaneous sporotrichosisMycoses.  47:62-68. 2004
2004 Surgical treatment of multiple skull abscesses associated with coccidioidomycosisMycoses.  47:69-71. 2004
2004 Guidelines for Treatment of CandidiasisClinical Infectious Diseases.  38:161-189. 2004
2004 Immunotherapy for invasive fungal infections: From bench to bedsideDrug Resistance Updates.  7:3-10. 2004
2003 Epidemiology of Aspergillus terreus at a University HospitalJournal of Clinical Microbiology.  41:5525-5529. 2003
2003 Donor-Related Coccidioidomycosis in Organ Transplant RecipientsClinical Infectious Diseases.  37:1265-1269. 2003
2003 Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United StatesAntimicrobial Agents and Chemotherapy.  47:3149-3154. 2003
2003 A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patientsClinical Infectious Diseases.  37:634-643. 2003
2003 A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjectsClinical Infectious Diseases.  36:1221-1228. 2003
2003 BlastomycosisInfectious Disease Clinics of North America.  17:21-40. 2003
2003 Current concepts in the management of fungal peritonitisCurrent Infectious Disease Reports.  5:120-124. 2003
2002 Blastomycosis: Gilchrist's disease revisitedCurrent Clinical Topics in Infectious Diseases.  61-77. 2002
2002 Fungal brain abscess in transplant recipients: Epidemiologic, microbiologic, and clinical featuresClinical Transplantation.  16:419-424. 2002
2002 Voriconazole versus liposomal amphotericin B for empirical antifungal therapy [1] (multiple letters)New England Journal of Medicine.  346:1745-1747. 2002
2002 Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent feverNew England Journal of Medicine.  346:225-234. 2002
2001 Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose studyAntimicrobial Agents and Chemotherapy.  45:3487-3496. 2001
2001 A lawyer from Honduras with fever and hypotensionInfections in Medicine.  18:453-460. 2001
2001 The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosisClinical Infectious Diseases.  33:1824-1833. 2001
2001 Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998Antimicrobial Agents and Chemotherapy.  45:3065-3069. 2001
2001 Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapyClinical Infectious Diseases.  33:690-699. 2001
2001 Therapy of Cryptococcal Meningitis in non-HIV-infected Patients.Current Infectious Disease Reports.  3:365-370. 2001
2001 Invasive mold infections in allogeneic bone marrow transplant recipientsClinical Infectious Diseases.  32:1319-1324. 2001
2001 Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected personsClinical Infectious Diseases.  32:1215-1220. 2001
2001 Infections in the neutropenic patient--new views of an old problem.Hematology online (ASH).  113-139. 2001
2001 Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32: 320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32: 321) [1]Clinical Infectious Diseases.  32:518-519. 2001
2001 Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a University HospitalDiagnostic Microbiology and Infectious Disease.  39:199-201. 2001
2001 Viral latency--the papillomavirus model.Developments in Biological Standardization.  106. 2001
2000 Candiduria: A randomized, double-blind study of treatment with fluconazole and placeboClinical Infectious Diseases.  30:19-24. 2000
2000 Sporotrichosis in Peru: Description of an area of hyperendemicityClinical Infectious Diseases.  30:65-70. 2000
2000 Microascus cinereus (anamorph Scopulariopsis) brain abscess in a bone marrow transplant recipientJournal of Clinical Microbiology.  38:395-397. 2000
2000 Fungal infections in ventricular assist devicesASAIO Journal.  46. 2000
2000 Practice guidelines for the management of cryptococcal diseaseClinical Infectious Diseases.  30:710-718. 2000
2000 Practice guidelines for the management of patients with blastomycosisClinical Infectious Diseases.  30:679-683. 2000
2000 Practice guidelines for the treatment of candidiasisClinical Infectious Diseases.  30:662-678. 2000
1999 Therapeutic Approach to Candida Sepsis.Current Infectious Disease Reports.  1:245-252. 1999
1999 Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropeniaNew England Journal of Medicine.  340:764-771. 1999
1999 Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected personsJournal of Infectious Diseases.  179:449-454. 1999
1998 Surveillance of cryptococcosis in Alabama, 1992-1994Annals of Epidemiology.  8:212-216. 1998
1998 Vertebral blastomycosis with paravertebral abscess: Report of eight cases and review of the literatureClinical Infectious Diseases.  26:413-418. 1998
1997 Cryptococcosis in non-HIV infected patients: A multicemer surveyClinical Infectious Diseases.  25:379. 1997
1997 Current trends in nosocomial candidemia: Results of a large multienter studyClinical Infectious Diseases.  25:357. 1997
1997 Blastomycosis in the immunocompromised patientSeminars in Respiratory Infections.  12:243-251. 1997
1997 Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndromeAmerican Journal of Medicine.  103:223-232. 1997
1997 Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.Clinical Infectious Diseases.  25:200-205. 1997
1997 A randomized, double-blind trial of parenteral low dose versus high dose interferon-β in combination with cryotherapy for treatment of condyloma acuminatumAntiviral Research.  35:41-52. 1997
1997 Treatment of blastomycosis with higher doses of fluconazoleClinical Infectious Diseases.  25:200-205. 1997
1996 Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.Clinical Infectious Diseases.  23:996-1001. 1996
1996 Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.Annals of Internal Medicine.  125:376-383. 1996
1996 Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group.Journal of Clinical Microbiology.  34:912-917. 1996
1996 Molecular subtype distribution of Cryptococcus neoformans in four areas of the United StatesJournal of Clinical Microbiology.  34:912-917. 1996
1996 Acyclovir with and without Prednisone for the Treatment of Herpes Zoster: A Randomized, Placebo-Controlled TrialAnnals of Internal Medicine.  125:376-383. 1996
1996 Fluconazole therapy for histoplasmosisClinical Infectious Diseases.  23:996-1001. 1996
1996 Therapeutic efficacy and complications of excisional biopsy of condyloma acuminatumSexually Transmitted Diseases.  23:273-276. 1996
1996 Treatment of lymphocutaneous and visceral sporotrichosis with fluconazoleClinical Infectious Diseases.  22:46-50. 1996
1995 Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.Clinical Infectious Diseases.  21:994-996. 1995
1995 Alopecia associated with fluconazole therapyAnnals of Internal Medicine.  123:354-357. 1995
1995 Azithromycin for Empirical Treatment of the Nongonococcal Urethritis Syndrome in Men: A Randomized Double-blind StudyJournal of the American Medical Association.  274:545-549. 1995
1995 Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.Clinical Infectious Diseases.  20:267-271. 1995
1995 A randomized, double-blind, placebo-controlled trial of systemically administered interferon-α, -β, or -γ in combination with cryotherapy for the treatment of condyloma acuminatumJournal of Infectious Diseases.  171:1081-1089. 1995
1995 Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of Cryptococcus neoformansJournal of Clinical Microbiology.  33:1890-1895. 1995
1995 Detection of specific antibodies in human blastomycosis by enzyme immunoassaySouthern Medical Journal.  88:1256-1259. 1995
1995 Intravascular catheter exchange and duration of candidemiaClinical Infectious Diseases.  21:994-996. 1995
1995 Itraconazole for the treatment of histoplasmosis and blastomycosisInternational Journal of Antimicrobial Agents.  5:219-225. 1995
1995 Treatment of blastomycosis with fluconazole: A pilot studyClinical Infectious Diseases.  20:267-271. 1995
1994 A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine.  331:1325-1330. 1994
1994 Comparative analysis of three antifungal susceptibility test methods against prospectively collected Candida speciesDiagnostic Microbiology and Infectious Disease.  18:89-94. 1994
1994 Erratum: NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis (American Journal of Medicine (August 1994) 97 (135-144))American Journal of Medicine.  97:497. 1994
1994 Intraocular blastomycosis: Case report and reviewClinical Infectious Diseases.  18:805-807. 1994
1994 NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosisAmerican Journal of Medicine.  97:135-144. 1994
1994 Pulmonary infection due to legionella cincinnatiensis in renal transplant recipients: Two cases and implications for laboratory diagnosisClinical Infectious Diseases.  18:385-389. 1994
1993 Blastomycosis in immunocompromised patientsMedicine.  72:311-325. 1993
1993 Penile Intraepithelial Neoplasia: Clinical Presentation and an Analysis of the Physical State of Human Papillomavirus DNAJournal of Infectious Diseases.  168:38-46. 1993
1993 SYPHILIS 100 YEARS AGO: PARALLELS WITH THE AIDS PANDEMICInternational Journal of Dermatology.  32:708-709. 1993
1993 Unusual causes of pneumonia. Problems with diagnosis and managementImmunology and Allergy Clinics of North America.  13:77-92. 1993
1992 Blastomycosis in patients with the acquired immunodeficiency syndromeAnnals of Internal Medicine.  116:847-853. 1992
1992 Human infection by genetically diverse SIVSM-related HIV-2 in West AfricaNature.  358:495-499. 1992
1991 Laboratory in the diagnosis and management of urinary tract infectionsMedical Clinics of North America.  75:313-325. 1991
1989 Gonococcal wound infectionSouthern Medical Journal.  82:1194. 1989
1989 Laser-induced nuclear orientation studies of 1-μs 85mRbSpectrochimica acta. Part A: Molecular spectroscopy.  45:63-73. 1989
1989 Strategic defense initiative six years later in the armyJournal of Aerospace Engineering.  2:111-118. 1989
1988 Kawasaki Syndrome Clusters in Harris County, Texas, and Eastern North Carolina: A High Endemic Rate and a New Environmental Risk FactorAmerican journal of diseases of children (1911).  142:441-444. 1988
1986 Complete Doppler coverage in laser optical pumping by wall-induced velocity-changing collisionsPhysical Review A.  34:2477-2479. 1986
1986 Optical pumping to the 6s5d states in atomic bariumPhysical Review A.  33:2798-2800. 1986
1984 Laser-induced nuclear orientation of 1-s Rbm85Physical Review Letters.  53:2230-2233. 1984
1982 The effects of ultra-violet laser radiation on cancerAcupuncture and Electro-Therapeutics Research.  7:27-38. 1982
1981 Nuclear structure study of24mNa using laser induced nuclear orientationHyperfine Interactions.  9:187-192. 1981
1981 Polarized sodium nuclei produced by laser optical pumping with velocity changing collisionsPhysical Review Letters.  47:236-239. 1981
1980 Laser-saturation spectroscopy with optical pumpingOptics Letters.  5:79-81. 1980
1980 Saturation spectroscopy with laser optical pumping in atomic bariumPhysical Review A.  21:1955-1968. 1980
1979 Magnetic moment of 24mNaPhysics Letters B.  88:242-244. 1979
1979 LASER SATURATION SPECTROSCOPY WITH OPTICAL PUMPING.Springer Series in Optical Sciences.  21:195-202. 1979
1978 Laser induced nuclear orientation: Intersection of laser and nuclear spectroscopyHyperfine Interactions.  4:50-60. 1978
1977 Laser induced nuclear orientation effectsNuclear Instruments and Methods.  141:429-432. 1977

Book

Year Title Altmetric
2011 Preface to the second edition 2011

Chapter

Year Title Altmetric
2015 Blastomycosis.  1138-1140. 2015
2014 Chronic Pneumonia.  860-873.e2. 2014
2012 Yeast infections after solid CHAP organ transplantation 2012
2011 Dematiaceous Fungal Infections.  2007-2008. 2011
2011 Fungal infections in solid organ transplant recipients.  511-524. 2011
2011 Sporotrichosis.  387-397. 2011
2011 Terbinafine.  113-119. 2011
2010 Blastomycosis.  1215-1218. 2010
2007 Superficial and mucosal fungal infections.  153-170. 2007

Principal Investigator On

  • Private Grant  awarded by SCYNEXIS 2017 - 2021
  • Private Grant  awarded by MAYNE PHARMA INC 2018 - 2021
  • Private Grant  awarded by CIDARA THERAPEUTICS, INC. - NEW 2016 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2017 - 2020
  • Private Grant  awarded by Gilead Sciences 2016 - 2020
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2013 - 2019
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2017 - 2018
  • Private Grant  awarded by T2 BIOSYSTEMS 2016 - 2018
  • Private Grant  awarded by IMMUNO-MYCOLOGICS, INC. 2015 - 2018
  • B Cell Subsets and Infectious Immunity to Cryptococcosis  awarded by ALBERT EINSTEIN COLLEGE OF MEDICINE 2012 - 2018
  • Private Grant  awarded by MERCK & COMPANY, INC. 2012 - 2017
  • A Prospective Cohort Study of Cryptococcus  awarded by Johns Hopkins University 2014 - 2017
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2015 - 2017
  • Private Grant  awarded by Gilead Sciences 2012 - 2016
  • Private Grant  awarded by Gilead Sciences 2011 - 2016
  • Private Grant  awarded by SCYNEXIS 2014 - 2016
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2011 - 2016
  • Private Grant  awarded by T2 BIOSYSTEMS 2014 - 2016
  • Private Grant  awarded by SCYNEXIS 2014 - 2016
  • Private Grant  awarded by FUNGISCOPE 2012 - 2016
  • Exserohilum Data  awarded by CDC - Centers for Disease Control and Prevention/DHHS 2015 - 2016
  • Private Grant  awarded by MERCK & COMPANY, INC. 2012 - 2016
  • Private Grant  awarded by Merck, Sharp, and Dohme (MSD) Research Foundation 2012 - 2016
  • Defining the Clinical, Diagnostic, Treatment and Outcomes Among Patients with Epidemic Mold Infections in the US Following Contaminated Methylprednisolone Infections MSG-08  awarded by CDC - Centers for Disease Control and Prevention/DHHS 2013 - 2016
  • Private Grant  awarded by T2 BIOSYSTEMS 2012 - 2015
  • Private Grant  awarded by SCYNEXIS 2013 - 2015
  • Prospective Observational Evaluation of the Association Between the Day 2 Vancomycin Exposure and Failure Rates Among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE)  awarded by Duke University 2014
  • Prospective Cohort Study of Cryptococcus  awarded by Johns Hopkins University 2014
  • Private Grant  awarded by T2 BIOSYSTEMS 2012 - 2014
  • Private Grant  awarded by T2 BIOSYSTEMS 2012 - 2014
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2008 - 2014
  • Private Grant  awarded by MERCK & COMPANY, INC. 2010 - 2013
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2007 - 2013
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2007 - 2013
  • Transplant Associated Infection Surveillance Network Phase II  awarded by CDC - NATIONAL CENTER FOR ZOONOTIC, VECTOR-BORNE, AND ENTERIC DISEASES 2010 - 2013
  • Private Grant  awarded by MERCK & COMPANY, INC. 2010 - 2013
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2012
  • Private Grant  awarded by MERCK & COMPANY, INC. 2009 - 2012
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2008 - 2011
  • Private Grant  awarded by SCHERING PLOUGH CORPORATION 2007 - 2011
  • Private Grant  awarded by Pfizer Pharmaceuticals 2008 - 2011
  • Private Grant  awarded by MERCK & COMPANY, INC. 2007 - 2011
  • Private Grant  awarded by MERCK & COMPANY, INC. 2008 - 2011
  • Private Grant  awarded by MERCK & COMPANY, INC. 2000 - 2010
  • Private Grant  awarded by Pfizer Pharmaceuticals 2007 - 2010
  • Investigator On

  • A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa  awarded by DUKE CLINICAL RESEARCH INSTITUTE 2018 - 2022
  • Private Grant  awarded by SERES THERAPEUTICS INC. 2018 - 2022
  • Private Grant  awarded by SERES THERAPEUTICS INC. 2018 - 2022
  • Private Grant  awarded by CIDARA THERAPEUTICS, INC. - NEW 2018 - 2021
  • Private Grant  awarded by AMPLYX PHARMACEUTICALS INC 2018 - 2021
  • Private Grant  awarded by CONTRAFECT CORPORATION 2018 - 2021
  • Private Grant  awarded by SUMMIT OXFORD LIMITED 2018 - 2021
  • Private Grant  awarded by VICAL, INC. 2018 - 2020
  • Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE)  awarded by Duke University 2014 - 2019
  • Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae (CRACKLE): a Prospective, Observational Cohort Study  awarded by Duke University 2017 - 2019
  • Private Grant  awarded by CRESTOVO LLC. 2017 - 2019
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2016 - 2018
  • Private Grant  awarded by ACTELION CLINICAL RESEARCH, INC. 2014 - 2017
  • Pre-Transplant Infectious Diseases Evaluation Clinic  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2014 - 2016
  • Private Grant  awarded by SERES THERAPEUTICS INC. 2015 - 2016
  • Private Grant  awarded by SERES THERAPEUTICS INC. 2015 - 2016
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2013 - 2015
  • Private Grant  awarded by CUBIST PHARMACEUTICALS 2014 - 2015
  • Private Grant  awarded by CEREXA, INC. 2013 - 2014
  • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 1978
  • Bachelor's Degree in General Studies, University of Alabama 1974
  • University of Washington Medical Center, Internship 1979
  • University of Washington Medical Center, Residency 1981
  • University of Washington Medical Center, Postdoctoral Fellowship 1983
  • Full Name

  • Peter Pappas